Plain-English translation of NCT04085887 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called that glows under special surgical lights to help doctors see brain tumors more clearly during surgery. The medication is injected into the bloodstream a few days before surgery, and then surgeons use special cameras in the operating room to spot tumor tissue that might otherwise be hard to see. Researchers want to find the safest and most effective dose of this medication for children and young adults.
Brain tumors in children can be hard to completely remove during surgery because some tumor cells are too small to see with the naked eye. By using this medication that glows, surgeons may be able to remove more of the tumor and leave healthy brain tissue untouched, which could improve outcomes for young patients.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the medication, then return to the hospital 1 to 5 days later for your scheduled brain tumor surgery — this is surgery you would be having anyway as part of your normal care. During surgery, the surgeon will use special imaging cameras to find and remove the tumor. After surgery, you will have follow-up visits on day 1–5, day 15, and day 30 to make sure you are recovering well and to check for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Stanford University
Enrollment target
~12 participants
Started
April 2026
Primary completion
December 2028
Age range
6 Months – 25 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nancy Sweeters
Stanford University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.